Xanthinol nicotinate, 300 mg/2 ml 2 ml 10 pcs.

• obliterating diseases of limb vessels: Raynaud’s disease, Buerger’s disease, obliterating endarteritis, obliterating atherosclerosis;
• diabetic angiopathy of limb vessels and retina;
• vascular thrombosis and embolism, strombophlebitic syndrome;
• trophic ulcers of the shins, bedsores, hard-to-heal wounds;
• transient ischemic attacks and other disorders of cerebral circulation;
• coronary atherosclerosis, hypercholesterolemia and hypertriglyceridemia;
• intrauterine and postpartum fetal asphyxia;
• migraine, Meniere’s syndrome.

.

Active ingredient

Xanthinol nicotinate

Composition

Active ingredients:

xanthinol nicotinate – 150 mg;

Injection water up to 1 ml.

How to take, the dosage

It is used intramuscularly and intravenously.

In adults, intramuscularly administered in a dose of 300 – 900 mg (2 – 6 ml of 15% solution) daily, for 2 – 3 weeks.

Intravenously injected slowly, in a dose of 1 to 2 ml of 15% solution 1 to 2 times daily, for 5 to 10 days (the patient must be in a horizontal position).

Intravenous drip is administered at a rate of 40 to 50 drops/min, the dose averages 150 to 900 mg. Dilute with 15% solution to 10 ml in dextrose 5% solution from 200 to 500 ml or in 0.9% sodium chloride solution to 200 ml.

In acute disorders of the blood supply to tissues simultaneously with parenteral administration of xanthinol nicotinate administered orally in 300 mg 3 times per day.

In children 5 to 10 mg/kg/day.

Interaction

In concomitant use with drugs with hypotensive effect (beta-adrenoblockers, ergot alkaloids, alpha-adrenoblockers, sympatholytics, ganglioblockers), with strophantine a sharp increase in their action is possible.

In concomitant use of xanthinol nicotinate with theophylline drugs an increase in plasma concentration of theophylline and an increased risk of its toxic effects are observed.

Anticonvulsants (carbamazepine, diphenin), barbiturate drugs accelerate the metabolism of xanthinol nicotinate and decrease its plasma concentrations.

The combined oral contraceptives, macrolide antibiotics (clarithromycin, erythromycin), interferon drugs and antifungals (ketoconazole, fluconazole) change the effect of xanthinol nicotinate, slow its metabolism and increase the plasma concentration of the drug.

When using xanthinol nicotinate in smokers, its plasma concentrations are lower than in non-smokers.

.

Special Instructions

With caution use in case of labile arterial pressure.

Particular caution should be used concomitantly with hypotensive drugs.

Impact on the ability to drive and operate machinery.

Perhaps use with caution in drivers of motor vehicles and in patients engaged in potentially hazardous activities.

Contraindications

• acute bleeding;
• hemorrhagic stroke;
• acute myocardial infarction;
• mitral stenosis;
• acute heart failureacute heart failure;
• chronic heart failure in decompensation;
• arterial hypotension;
• gastric and duodenal ulcer in the acute phase;
• acute renal failure;
• glaucoma;
• pregnancy (especially the first trimester);
• breastfeeding;
• high sensitivity to xanthinol nicotinate.

.

Side effects

• reduction of blood pressure;
• current feeling of warmth, redness of the skin, weakness, dizziness;
• commonly – nausea, diarrhea, anorexia, gastralgia;
• with prolonged use – impaired glucose tolerance, increased levels of transaminases and alkaline phosphatase, uric acid in serum;
• allergic reactions.

.

Overdose

Symptoms of intoxication occur 4 – 5 hours after administration of xanthinol nicotinate and last for 12 hours.

In the beginning there may be hot flashes, hyperemia of the upper half of the body, nausea, dizziness, tachycardia, decreased blood pressure; later – increase in temperature, agitation, loss of consciousness, areflexia, tonic-clonic convulsions, vomiting.

There is no specific antidote. Measures of care include discontinuation of the drug, supportive and symptomatic therapy to correct the resulting impairment, respiratory support, control of blood pressure levels, and management of the convulsion syndrome.

.